Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1989 Jun;115(3):269–275. doi: 10.1007/BF00391701

Uptake and release of iodine-labelled m-iodobenzylguanidine in a neuroblastoma cell culture system and its importance in neuroblastoma therapy

Volker Paffenholz 1, Uwe Ebener 1,✉, Bernhard Kornhuber 1
PMCID: PMC12211613  PMID: 2753929

Abstract

A neuroblastoma cell line was established from bone marrow of a patient in stage IV of the disease and used as a model system in order to elaborate experimental data of importance in neuroblastoma therapy, such as cell-drug interactions, the mode of uptake and conditions for storage and release m-Iodo benzylguanidine (MIBG) is rapidly taken up from culture medium, giving high concentrations of cell-bound radioactivity reaching a maximum level 4 h after the addition of the compound. A removal of the radiopharmacon from the culture medium causes a dramatic loss of cell-associated radioactivity, suggesting that neuroblastoma cells are not able to retain MIBG in a drug-free environment.

Replacement of labelled by unlabelled MIBG prevents a similar release and maintains high levels of cellular radioactivity. Variations of cell culture conditions only result in minor changes of uptake rates, whereas a pretreatment with drugs used in neuroblastoma chemotherapy harms the cells extensively: even after a short-term exposure the cells lose the capacity for MIGB uptake and fail to recover within a long period of incubation in growth medium. The importance of our results is discussed, leading to the following suggestions:

  1. The performance of radiotherapy with labelled MIBG is recommended prior to the chemotherapy protocols.

  2. Therapeutically effective radioactivity in tumor tissues may be maintained by the additional infusion of unlabelled MIGB.

Key words: Uptake studies, radiopharmacon, tumor therapy

Footnotes

Supported by the Deutsche Krebshilfe, grant M 48/85/Ko 1

References

  1. Berthold F (1985a) Current concepts on the biology of neuroblastoma. Blut 50:65–74 [DOI] [PubMed] [Google Scholar]
  2. Berthold F (1985b) Multizentrische Therapiestudie der Gesellschaft für Pädiatrische Onkologie, Studienprotokoll NB 85
  3. Buck J, Bruchelt G, Girgert R, Treuner J, Niethammer D (1985) Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 45:6366–6370 [PubMed] [Google Scholar]
  4. Christiansen H, Franke F, Bartram CR, Adolph S, Rudolph B, Harbott J, Reiter A, Lampert F (1987) Evolution of tumor cytogenetic aberrations and n-myc oncogene amplification in a case of disseminated neuroblastoma. Cancer Genet Cytogenet 26:235–244 [DOI] [PubMed] [Google Scholar]
  5. Edeling CJ, Büchler-Frederiksen P, Kamper J, Jeppesen P (1986) Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine. Nuklearmedizin 25:172–175 [PubMed] [Google Scholar]
  6. Hill BT, Whelan RDH (1981) Assessment of the sensitivity of cultured human neuroblastoma cells to anti-tumour drugs. Pediatr Res 15:1117–1122 [DOI] [PubMed] [Google Scholar]
  7. Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, zum Winkel K (1983) Szintigraphische Darstellung eines Neuroblastoms. NucCompat 14:320–326 [Google Scholar]
  8. Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, zum Winkel K (1984a) Scintigraphy of a neuroblastoma with I-131-meta-iodobenzylguanidine. J Nucl Med 25:773–775 [PubMed] [Google Scholar]
  9. Kimmig B, Brandeis WE, zum Winkel K, Feine U, Treuner J, Niethammer D, Müller-Schauenburg W, Fischer M, Kahn K, Gutjahr P, Munkner T, Yssing M, Vossberg H (1984b) Scintigraphic imaging of neuroblastoma with 131I-mIBG and first attempts of its therapeutic use. Nuklearmedizin 21:474–476 [Google Scholar]
  10. Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Georgi P (1985) Scintiscan imaging of benign and malignant tumours of the sympathetic nervous system via meta-iodobenzylguanidine. Röntgenblätter 38:154–158 [PubMed] [Google Scholar]
  11. Kimmig B, Brandeis WE, Eisenhut M, Ludwig R, Adolf J (1986) Scintigraphic imaging of neuroblastoma using meta-iodobenzylguanidine. Klin Pädiatr 198:224–229 [DOI] [PubMed] [Google Scholar]
  12. Klingebiel T, Feine U, Niethammer D, Müller-Schauenburg W, Schwabe D, Maul FD, Gerein V, Fischer M, Gahr M, Kraz K, Wehinger D, Weinel P, Berthold F, Hunnemann D, Treuner J (1986) First results of treatment of children with metastatic neuroblastoma and neuroblastoma in relapse with metaiodobenzylguanidine. Klin Pädiatr 198:230–236 [DOI] [PubMed] [Google Scholar]
  13. Mitchell JR, Oates JA (1970) Guanethidine and related agents. I. Mechanism of the selective blockade of adrenergic neurons and its antagonism by drugs. J Pharmacol Exp Ther 172:100–107 [PubMed] [Google Scholar]
  14. Müller-Gärtner HW, Erttmann R, Helmke K (1985) Die Szintigraphie mit Radiojod [Meta-Jod-Benzylguanidin] in der Diagnostik des Neuroblastoms. Nuklearmedizin 24:222–226 [PubMed] [Google Scholar]
  15. Niderson M, Collier B (1975) Drugs inhibiting adrenergic nerves and structures innervated by them. In: Goodman CS (ed) The pharmacological basis of therapeutics, 5th edn. Macmillan, New York, pp 553–564 [Google Scholar]
  16. Paffenholz V, Hoffecker H, Gusettis E, Ebener U, Kornhuber B (1988) Evaluation of [131I]-MIBG uptake and release in a neuroblastoma cell culture system and its clinical importance. J Cancer Res Clin Oncol (Suppl) 114:S2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ross RA, Joh TH, Reis DJ, Spengler BA, Biedler JL (1979) Neurotransmitter-synthesizing enzymes in human neuroblastoma cells: relationship to morphological diversity. In: Evans AE (ed) Advances in neuroblastoma research. Raven, New York, pp 151–160 [Google Scholar]
  18. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Beierwaltes WH (1984) Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterization. Clin Endocrinol 20:189–203 [DOI] [PubMed] [Google Scholar]
  19. Siegel SE (1982) Clinical characteristics, prognostic factors, and outcome, pp 873–876. In: Seeger RC (moderator) Neuroblastoma: clinical perspectives, monoclonal antibodies, and retinoic acid. Ann Intern Med 97:873–884 [DOI] [PubMed] [Google Scholar]
  20. Siegel MM, Chung HS, Rucker N, Siegel SE, Seeger RC, Isaacs H, Benedict WF (1980) In vitro and in vivo preclinical chemotherapy studies of human neuroblastoma. Cancer Treat Rep 64:975–979 [PubMed] [Google Scholar]
  21. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH (1979) Imaging the adrenal medulla with an I-131-labelled antiadrenergic agent. J Nucl Med 20:155–158 [PubMed] [Google Scholar]
  22. Wieland DM, Wu JI, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131I-iodobenzylguanidine. J Nucl Med 21:349–353 [PubMed] [Google Scholar]
  23. Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh D, Mangner TJ, Swanson DP, Beierwaltes WH (1981) Imaging the primate adrenal medulla with 123I and 131I metaiodobenzylguanidine: concise communication. J Nucl Med 22:358–364 [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES